CRISPR-Based Therapies Revolutionize the Treatment of Sickle Cell Disease, Underwhelm Investors
The field of gene editing has taken a leap forward with the recent approvals of two CRISPR-based drugs, Casgevy and Lyfgenia, for the treatment of sickle cell disease (SCD). These groundbreaking therapies offer potential for treating this previously incurable disease, generating excitement and hope for patients and the science around gene editing. The Money Pricing: … Read more